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Abstract

In this review, we focus on summarizing everything that is known about the
neurological effects of Severe Acute
Respiratory Syndrome Coronavirus 2
(SARS-COV-2). It has been shown that
Coronavirus Disease 2019 (Covid-19) may
result in neuromuscular disorders or damage to nerves outside of the brain and spinal
cord, which may lead to weakness, numbness, and pain. Published literature has stated that SARS-COV-1 may infect the central nervous system and due to its similarities to SARS-COV-2, we suspect that
SARS-COV-2 has the same potential. We
conclude that Covid-19 has neurological
manifestations. Further research should be
done in this field to understand the full
extent of this virus.

Introduction

In December of 2019, Severe Acute
Respiratory Syndrome Coronavirus 2
(SARS-COV-2) emerged in Wuhan, China,
and rapidly spread across many other countries.1 Early studies reported a possible link
from a wild animal market for most cases of
infection, indicating the likelihood of it
being zoonotic in nature. It is suspected that
the reservoir for SARS-COV-2 is a Chinese
horseshoe bat, however further studies have
indicated a human-to-human transmission
model of SARS-COV-2 through droplets or
direct contact is the most likely method of
transmission amongst most patients.2-5 With
the interconnected nature of our globalized
society, travel has become a very prevalent
epidemiological link in disease transmission, especially during the current pandemic. On March 11, 2020, the World Health
Organization
officially
classified
Coronavirus Disease 2019 (COVID-19) as
a pandemic.1 People with prolonged contact
with an infected individual are at high risk
of contracting the virus. To gain more accurate data, it is useful to use an electronic
literature search to gather data from published findings and case studies.6
In this paper, we review literature concerned with the neurological implications of

Coronavirus Disease 2019 (Covid-19) in
hopes of shedding light on potentially overlooked, yet significant, neurologic complications of the virus. Published literature was
compiled using Pubmed and Google
Scholar as search engines and Sars
Neurology, Sars Cov 2 Neurology as keywords used in the search. Studies lacking
the focus on neurology were excluded in
our search. Very little information is known
about how Severe Acute Respiratory
Syndrome Coronavirus 2 (Sars-Cov-2) interacts with the central and peripheral nervous system, and new information about the
virus is being added to the literature every
day. Concerns of neurological complications in patients suffering from Covid-19
were raised when research reports surfaced
from Wuhan, China, suggesting that neurologic symptoms are apparent in 36.4% of
patients and are more common in patients
with severe infection (45.5%).7 We compare
this newfound data of SARS-COV-2 to the
limited amount of published literature that
has surfaced in regards to the neurological
complications of SARS-COV-1 in hopes to
advance the knowledge of the scientific
community on the neurological pathology
of SARS-COV-2.

Pathology of SARS-COV-2

The family of Coronaviridae is singlestranded, positive-sense RNA viruses that
are surrounded by a viral envelope. The
suborder Cornidovineae is split up into
alpha coronavirus, beta coronavirus,
gamma coronavirus, and delta coronavirus.8
Most coronaviruses share mainly similar
genomes and the open reading frames 1a
and 1b compromise almost two-thirds of the
genome. The remaining portion of the genome is responsible for encoding structural
proteins such as the nucleocapsid, envelope,
and membrane proteins.1,6 SARS-COV-2 is
enveloped by a lipid bilayer that contains
viral fusion proteins that aid with the fusion
of viruses to the cell. When SARS-COV-2
injects its genome into the cell, the virus
hijacks the host’s ribosomes for protein production with the help of its viral RNA 5’ cap
and a poly-A tail.6,9 The first protein produced by the viral positive-sense RNA is an
RNA Dependent RNA Polymerase (RDRP).
RDRP is a replicase and it is responsible for
transcribing a negative-sense RNA strand
by reading the original positive sense RNA
strand from the 5’ to the 3’ end. Once the
negative-sense RNA strand is complete, the
RDRP reads the negative-sense RNA
strands from the 3’ to the 5’ end to produce
another positive sense RNA strand.4
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Attachment of SARS-COV-2 to
ACE2 receptors

SARS-COV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry point
in the early stages of infection. It does this by
attaching its spike S1 protein to ACE2’s
enzymatic domain, which causes the cell to
undergo endocytosis. After this occurs, there
is a down-regulation of surface ACE2 proteins, which leads to an increased level of
angiotensin II. The virus also requires that
the S protein is primed by serine protease
TMPRSS2, a protein on the host cell.10 The
S protein is a class I viral fusion protein,
which means that it is a trimer in the fusion
states, relies on proteolytic cleavage for activation and contains alpha-helices and heptad
repeats (HR) regions.11 The organs most
affected by SARS-COV-2 are the lungs. The
virus accesses the host cells through the
enzyme angiotensin-converting enzyme 2
(ACE 2) which is abundant in type II alveolar cells in the lungs.6 Furthermore, it has
been shown that glial cells and neurons of the
central nervous system express ACE 2 receptors as well, making nervous tissue a possible
infection site for SARS-COV-2.9
[page 15]
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Zinc as a countermeasure

It has been shown that Zinc 2+ ion is
able to inhibit coronavirus replication in
vitro, with a direct relationship between the
increased intracellular concentration of Zn
2+ and a decrease in the viral byproduct of
RDRP.10
Charged ions such as Zn 2+ are unable
to pass the hydrophobic part of the cell
membrane through simple diffusion, requiring the use of a membrane ionophore.
Pyrithione, one ionophore that exists in the
body, provides a mechanism to allow the
Zinc to enter ions into the cytosol of the
cell.12
This may help in the resistance of the
spread infection from SARS-COV-2,13
however it has not been found how increased levels of zinc can aid in preventing or
combating the suspected neurological symptoms of SARS-COV-2. More research
should be done to reveal how we can use
zinc to sabotage viral reproduction in order
to prevent or treat neurological symptoms
of SARS-COV-2.

Furthermore, cytokine release syndrome can result in acute necrotizing encephalopathy (ANE), a rare hemorrhagic encephalopathy related to viral infection and
cytokine release syndrome. This condition
has been observed in influenza patients as
well as a small number of SARS-COV-2
patients.18 Viral particles do not require a
direct invasion the central nervous system
for ANE to develop, however. A breakdown
of the blood-brain barrier, seizures, and
strokes are complications ANE.
Subsequently, neuroinflammation can
occur as a result of the cytokine storm, specifically as a result of IL-6. IL-6 further
activates the production of other cytokines,
which worsens the encephalopathy in a
positive feedback-like manner.11

Neurological symptoms of SARSCOV-1

It is known that zinc is a major trace
element found in the central nervous
system, and plays a crucial role in proper
neurological functioning. Zinc deficiency
has been found to be related to oxidative
stress as well as impairments in olfaction
and gustation,14 both of which have been
observed in SARS-COV-2 patients.
Zinc has also been found to be a major
factor in the human body’s acute immune
response. Zinc floods into cellular compartments of vital organs, especially the liver,
causing transient hypozincemia in the host’s
serum during early responses to infection.
This zinc redistribution also creates an
unfavorable environment for microbial
pathogens, who need zinc to survive.15,16
One possible complication of SARSCOV-2 is the potential for cytokine release
syndrome, characterized by a rapid cytokine
storm.17 This rapid increase in cytokines,
such as Interleukin-6 (IL-6), is attributed to
the immune system’s response to viral
infection by SARS-COV-2. Cytokine
storms can cause complications including
respiratory failure and neurological disorders. Zinc deficiency promotes IL-6 production, along with other immune markers.
Even more so, zinc deficiency can promote
immune cell activation and a pro-inflammatory response.11

Towards the end of 2002 a coronavirus
disease emerged in China, similar to SARSCOV-2, and spread throughout parts of
Asia. The virus was named SARS-COV,
now denoted as SARS-COV-1.1 SARSCOV-1 has a high mortality rate in patients
older than the age of 65, at approximately
50%.19 A limited amount of published literature has surfaced in regards to the neurological complications of SARS-COV-1 and
it has been reported that these complications appear 2-3 weeks into the course of
the illness. The neurological complications
include but are not limited to axonal peripheral neuropathy and myopathy.19
Furthermore, it has been reported that
patients with SARS-COV-1 also had olfactory neuropathy with an onset of three
weeks into the illness,5 similar to reported
symptoms of SARS-COV-2. Alteration in
smell and taste were frequently reported by
mildly symptomatic patients of SARSCOV-2 infection and were often the first
apparent symptom of the disease.2 These
results must be interpreted with caution,
however, due to the limitations of the study
that has made these findings. A doubleblind study would be best to determine such
results and this study is not the gold standard in medicine. When transgenic mice
were infected intranasally, researchers
discovered the virus residing in the thalamus and brainstem, suggesting that the neural pathway of viral particles originated in
the olfactory nerve.7
After the SARS-COV-1 outbreak there
had been several proposed mechanisms of
neurological manifestations in SARS-COV1 patients.17 The different neurological
symptoms observed in this study were poly-
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The role of Zinc in acute
immune response and neurological complications

neuropathy, and rhabdomyolysis, which
may result from systemic inflammatory
response syndrome.19,20 The pathogenetic
role of a direct attack of SARS-COV-1 on
the peripheral nerves and muscles was
suspected in this report.17 Multiple factors
of cerebral infarction in SARS-COV-1
patients included: hypercoagulable status
related to both SARS-COV-1 and the usage
of intravenous immunoglobulin, septic and
cardiogenic shock, and possible viral
inflammation of blood vessels.17 Because of
the limited number of reported cases of
SARS-COV-1 patients with neurological
symptoms, the clear pathogenesis of the
neurological problems in SARS-COV-1 is
not well understood.
Furthermore, there have been several
case studies during the SARS-COV-1 outbreak that reported patients experiencing
fever, chills, productive cough, and diarrhea. In one particular case study, a patient
began to vomit, and experience episodes of
four-limb twitching approximately one
week after hospital admission. Within a few
hours, the patient became confused and
disorientated.21 The researchers performed
further virologic investigations due to the
presentation of the seizures. The researchers
decided to analyze the extracted RNA from
the cerebrospinal fluid (CSF) and serum
samples of the patient by real-time quantitative RT-PCR assay targeting the polymerase
region of the SARS-COV-1 genome.21 The
researchers found that the SARS-COV-1
RNA was present in both the CSF and the
serum, with viral loads of 6884 and 6750
copies/mL, respectively.21 These results
suggest meningitis infection by SARSCOV-1.

Neurological symptoms of SARSCOV-2

One report surfacing from Wuhan,
China indicates that neurologic symptoms
were seen in 36.4% of patients with SARSCOV-2, and were more common in patients
with severe infection (45.5%).7 The neurological symptoms discussed were myopathy, loss of sense of smell or taste, and stroke. More nonspecific symptoms were also
implicated in the study such as lower level
of consciousness, headaches, dizziness, and
seizure.7
These symptoms are grouped into several categories, including acute cerebrovascular disease-related symptoms, intracranial infection-related symptoms, peripheral
nervous system symptoms, and neuromuscular symptoms.22 With regards to headaches, one study reported that 8% of patients
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experienced them, and another study reported that 34% of patients complained of headaches.12,19
Among confirmed patients with
COVID-19, a significant number of severely affected individuals were elderly. High
D-dimer levels were observed in COVID19 patients in one intensive care unit (ICU),
predisposing them to a hypercoagulable
state.22 A lower platelet count in critical
cases, as found by the same study, suggests
that patients with hypertension who are
infected by SARS-CoV-2 may experience
increased blood pressure and are at a higher
risk for cerebrovascular hemorrhage, in
addition to the fact that elderly patients are
already a high-risk group for developing
cerebrovascular disease.22
Moreover, intracranial infection-related
symptoms such as headache, epilepsy, and
disturbance of consciousness have been
reported by doctors observing these symptoms in COVID-19 patients.18 Past evidence from SARS-COV-1 revealed a possible
central nervous system infection for coronaviruses, and given the similar genetic
sequences of SARS-COV-1 and SARSCOV-2, and their use of the same ACE2
receptor in order to gain entry to host cells,
neurologists should consider the possibility
of central nervous system infection by
SARS-CoV-2.18,22
A case study with 214 patients with
COVID 19 revealed that 78 (36.4%) suffered from neurological symptoms.7 The researchers and neurologists analyzed the data
and categorized the symptoms into three
categories. If the central nervous system
had been affected, the patients developed
symptoms such as dizziness, headache,
impaired consciousness, acute cerebrovascular disease, ataxia, and seizure. Patients
with affected peripheral nervous system had
clinical manifestations including taste,
smell, and vision impairment as well as
nerve pain.7 The final category was for
patients who suffered sustained injury to
their skeletal-muscular system. Patients
who had a more severe infection, as well as
those who were older and had other underlying disorders such as hypertension, were
more likely to have these neurological symptoms. Patients with more severe infection
were 5.1% more likely to have acute cerebrovascular diseases, 12.4% more likely to
have impaired consciousness, and 14.5%
more likely to have a skeletal muscle
injury.7
Recent literature has reported cases of
Guillain-Barré Syndrome (GBS) as a complication of the novel coronavirus.8,23 GBS
is a polyneuropathy that commonly develops post infection. Immune attack of nerve
cells causes the typical tingling in the extre-

mities that is commonly reported as being
the first symptom of GBS. Little is known
about the interaction between SARS-COV2 infection and GBS, however clinicians
should be aware of the possibility of GBS
complication when treating patients tested
positive for SARS-COV-2.

Discussion and conclusions

Much of current knowledge of the
SARS-COV-2 virus revolves around its
relatedness to SARS-COV-1. Due to the
understanding that most coronaviruses
share mainly similar genomes and the open
reading frames, 1a and 1b, comprise almost
two-thirds of the genome, researchers can
look into previously published research
reports of the SARS-COV-1 outbreak in the
early 2000’s in order to predict various
implications of SARS-COV-2. This is vital
to understanding overlooked avenues of
research such as neurological implications
of SARS-COV-2.
SARS-COV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry point
in the early stages of infection, as seen in
previous studies. It has been shown that
glial cells and neurons of the central nervous system express ACE 2 receptors,9 and
that the central nervous system is capable of
invasion by SARS-COV-1 in a rat model.7
This effectively makes nervous tissue a possible target of infection by the novel coronavirus.
Zinc 2+ ion is able to inhibit coronavirus replication in vitro, however, the mechanism with which increased zinc levels can
aid in preventing or combating the suspected neurological symptoms of SARS-COV2 is still unknown. More research should be
done in this avenue to determine how to
treat neurological symptoms of SARSCOV-2, and zinc supplementation should be
considered.
Furthermore, one possible complication
of SARS-COV-2 is the potential for cytokine release syndrome, characterized by rapid
cytokine storms.17 This rapid increase in
cytokines is attributed to the immune system’s response to viral infection by SARSCOV-2. Cytokine storms can cause complications including respiratory failure and
neurological disorders. Zinc deficiency promotes cytokine production, along with other
immune markers, and therefore can lead to
further complications. Zinc deficiency has
also been found to be related to oxidative
stress as well as impairments in olfaction
and gustation,14 both of which have been
observed in SARS-COV-2 patients, adding
another possible benefit of zinc supplementation.
[Neurology International 2020; 12:8639]

A limited amount of published literature
has surfaced in regards to the neurological
complications of SARS-COV-1. However,
it has been reported that these complications appear 2-3 weeks into the course of
the illness and the reported neurological
complications include axonal peripheral
neuropathy and myopathy.19 Interestingly, it
has also been reported that patients with
SARS-COV-1 also had olfactory neuropathy with an onset of three weeks into the
illness, similar to patients suffering with
SARS-COV-2. Different neurological symptoms observed in the SARS-COV-1 outbreak were polyneuropathy and rhabdomyolysis, which may result from systemic
inflammatory
response
syndrome.
Researchers suspect a pathogenetic role of a
direct attack of SARS-COV-1 on the peripheral nerves and muscles. Finally, researchers found that the SARS-COV-1 RNA
was present in both the CSF and the serum
of infected patients. This leads us to believe
that the virus has the capability to cause a
meningitis infection due to the observation
of viral loads in CSF of several patients.
Clinicians should be aware of this complication.
Reports surfaced from Wuhan, China
indicating that clinicians observed neurologic symptoms in 36.4% of patients with
SARS-COV-2. The neurological symptoms
discussed were myopathy, loss of sense of
smell or taste, and stroke. These observed
symptoms were similar to that observed in
the SARS-COV-1 outbreak, indicating yet
again a correlation between SARS-COV-1
and SARS-COV-2. More nonspecific symptoms were also implicated in the reports
that surfaced from Wuhan, including
depressed consciousness, headaches, dizziness, and seizures. With regards to headaches, one study reported that 8% of patients
experienced them, and another study reported that 34% of patients complained of headaches. A significant number of severely
affected individuals had high D-dimer
levels predisposing the individuals to a
hypercoagulable state. A lower platelet
count in critical cases suggests that patients
with hypertension who are infected with
SARS-CoV-2 may experience increased
blood pressure and are at a higher risk for
cerebrovascular hemorrhage. Past evidence
from SARS-COV-1 revealed a possible central nervous system infection for coronaviruses, and given the similar genetic sequences of SARS-COV-1 and SARS-COV-2,
especially the similarity in their use of the
same ACE2 receptor in order to gain entry
to host cells, neurologists should consider
the possibility of central nervous system
infection by SARS-CoV-2. Lastly, recent
literature reported cases of Guillain-Barré
[page 17]
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Syndrome (GBS) as a complication of the
novel coronavirus post infection.
Knowledge on the novel coronavirus is
surfacing every day, and as time continues
our understanding of how to combat the
current pandemic increases. We write this
review with the goal of enriching the knowledge of physicians and other healthcare
workers who are treating patients infected
with the virus, and hope that unforeseen
neurological complications in such patients
can be avoided.
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